Menu
No results found.
Weekly Share Price & Valuation Overview
Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Revenue growth ≥10% indicates solid top-line momentum.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Debt/EBITDA >4 — elevated leverage vs earnings capacity.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 1.21B
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 905.97M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 316.27M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD 202.89M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- USD 12.90M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 2.51
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.45
- Shares Outstanding
- 117.27M
- Float Shares
- 98.91M
- Implied Shares Outstanding
- 117.27M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
17.45%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
4.08%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
64.15%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-16.67%
- ROA Return on assets: net income ÷ total assets.
-
0.52%
- ROE Return on equity: net income ÷ shareholder equity.
-
-9.28%
- Revenue Growth Strong Year-over-year revenue growth.
-
29.30%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
76.00%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
64.40%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 5.83
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.59
- Total Cash Cash and equivalents.
- USD 613.73M
- Total Debt Short + long-term interest-bearing debt.
- USD 289.56M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- USD -324.16M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 22.45
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- USD 76.27M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- USD 43.09M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
24.12%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
13.62%
- Cash Conversion (OpCF/EBITDA)
- 5.91
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.